You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 11, November 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, LONDON, APRIL 27 TO APRIL 30, 1987-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Does Radical Mastectomy Still Have a Place in the Treatment of Primary Operable Breast Cancer?

William A. Maddox, MD; John T. Carpenter, Jr, MD; Henry T. Laws, MD; Seng-Jaw Soong, PhD; Gretchen Cloud, MS; Charles M. Balch, MD; Marshall M. Urist, MD

Arch Surg. 1987;122(11):1317-1320.


Abstract

• This study (Alabama Breast Cancer Project) reports the ten-year surgical results of a prospective randomized trial comparing Halsted radical mastectomy (RM) with modified radical mastectomy (MRM) for breast cancer. We entered 311 patients in the study between 1975 and 1978. Patients with histologically positive axillary lymph nodes were randomized after operation to receive melphalan or intermittent intravenous cyclophosphamide, methotrexate, and fluorouracil for one year. After a median follow-up of ten years, there was no significant difference in the survival of the two groups (RM, 71%; MRM, 64%). Local recurrence after RM was significantly lower than after MRM. A subset of patients with more advanced cancers (T3 and T2 with clinically positive axillary nodes) experienced significantly better survival at ten years following RM compared with MRM (59% vs 38%, respectively). These results indicate that overall survival is similar for patients treated by either RM or MRM. However, there is subset of patients with more advanced cancers whose ultimate survival can be favorably influenced by RM.

(Arch Surg 1987;122:1317-1320)



Author Affiliations

From the Section of Surgical Oncology, Department of Surgery (Drs Maddox, Laws, and Urist), the Section of Hematology/Oncology, Department of Medicine (Dr Carpenter), and the Biostatistics Unit, Comprehensive Cancer Center (Dr Soong and Ms Cloud), University of Alabama in Birmingham; and the Department of General Surgery, M. D. Anderson Hospital, Houston (Dr Balch). Dr Laws is now with the Department of Surgery, Carraway Methodist Medical Center, Birmingham, Ala.


Footnotes

Accepted for publication July 14, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 27, 1987.

Reprint requests to Section of Surgical Oncology, Department of Surgery, Suite 321, Kracke Bldg, University Station, Birmingham, AL 35294 (Dr Maddox).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Natural Killer Cells and the Guy's Hospital Trials-Reply
MADDOX et al.
Arch Surg 1988;123:914-914.
ABSTRACT  

Natural Killer Cells and the Guy's Hospital Trials
EVANS
Arch Surg 1988;123:913-914.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.